[바이오코리아2026] 김열홍 유한양행 사장 "올해 제2 렉라자 탄생"

Yuhan Corp is accelerating its transition from the single-product success of Leclaza to a sustainable R&D powerhouse by advancing four high-potential pipelines toward imminent licensing-out deals. Their strategic pivot toward Targeted Protein Degradation (TPD) as a core 'New Modality' signals a shift in the biotech landscape where internal platform development is becoming crucial for long-term competitiveness beyond traditional antibody treatments.